MXPA03003575A - Procedimiento para elaborar la forma b del cristal de nateglinida. - Google Patents
Procedimiento para elaborar la forma b del cristal de nateglinida.Info
- Publication number
- MXPA03003575A MXPA03003575A MXPA03003575A MXPA03003575A MXPA03003575A MX PA03003575 A MXPA03003575 A MX PA03003575A MX PA03003575 A MXPA03003575 A MX PA03003575A MX PA03003575 A MXPA03003575 A MX PA03003575A MX PA03003575 A MXPA03003575 A MX PA03003575A
- Authority
- MX
- Mexico
- Prior art keywords
- crystals
- nateglinide
- type
- further characterized
- drying
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 107
- 229960000698 nateglinide Drugs 0.000 title claims abstract description 44
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000001035 drying Methods 0.000 claims abstract description 14
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 239000012453 solvate Substances 0.000 claims abstract description 6
- 230000007704 transition Effects 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- -1 nateglinide hydrates Chemical class 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- OELFLUMRDSZNSF-OFLPRAFFSA-N (2R)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid Chemical compound C1CC(C(C)C)CCC1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-OFLPRAFFSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
- C07C227/42—Crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000324375 | 2000-10-24 | ||
| PCT/JP2001/009293 WO2002034713A1 (en) | 2000-10-24 | 2001-10-23 | Process for producing b-form nateglinide crystal |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03003575A true MXPA03003575A (es) | 2003-07-14 |
Family
ID=18801920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03003575A MXPA03003575A (es) | 2000-10-24 | 2001-10-23 | Procedimiento para elaborar la forma b del cristal de nateglinida. |
Country Status (18)
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1283054A4 (en) * | 2000-03-17 | 2006-04-12 | Ajinomoto Kk | MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF |
| CA2425533C (en) * | 2000-10-18 | 2010-04-20 | Ajinomoto Co., Inc. | Methods for producing acylphenylalanine |
| DE60129728T2 (de) * | 2000-10-18 | 2008-04-24 | Ajinomoto Co., Inc. | Verfahren zur herstellung von nateglinid-kristallen |
| DK1334720T3 (da) * | 2000-10-24 | 2009-01-19 | Ajinomoto Kk | Nateglinid-indeholdende fremstillinger |
| ES2321911T3 (es) * | 2000-10-24 | 2009-06-15 | Ajinomoto Kk | Preparaciones farmacologicas hidrofilas que contienen nateglinida. |
| EP1496048A4 (en) * | 2002-04-15 | 2006-08-02 | Ajinomoto Kk | NEW NATEGLINID CRYSTAL |
| US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
| US6861553B2 (en) | 2002-07-03 | 2005-03-01 | Teva Pharmaceuticals Industries Ltd. | Process for preparing nateglinide and intermediates thereof |
| US7420084B2 (en) * | 2002-07-18 | 2008-09-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7148376B2 (en) | 2002-07-18 | 2006-12-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| WO2004009532A1 (en) * | 2002-07-18 | 2004-01-29 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US7534913B2 (en) * | 2002-07-18 | 2009-05-19 | Teva Pharmaceutica Industries Ltd. | Crystalline form of nateglinide |
| US7358390B2 (en) | 2002-07-18 | 2008-04-15 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| EP1535900B1 (en) * | 2003-11-26 | 2006-12-27 | A.M.S.A. ANONIMA MATERIE SINTETICHE E AFFINI S.p.A. | Process for the preparation of nateglinide, preferably in b-form |
| CA2563793A1 (en) * | 2004-05-07 | 2005-11-24 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of nateglinide |
| US20070231393A1 (en) * | 2004-05-19 | 2007-10-04 | University Of South Carolina | System and Device for Magnetic Drug Targeting with Magnetic Drug Carrier Particles |
| US20080096970A1 (en) * | 2004-05-20 | 2008-04-24 | Sundaram Venkataraman | Stable Nateglinide Form B Compositions |
| US7425648B2 (en) | 2005-01-03 | 2008-09-16 | A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. | Process for the preparation of nateglinide, preferably in B-form |
| CN101111266A (zh) * | 2005-01-31 | 2008-01-23 | 味之素株式会社 | 含有降血糖药的用于改善或治疗糖耐量异常、临界性糖尿病、胰岛素抵抗性和高胰岛素血症的药物组合物 |
| WO2007135533A1 (en) * | 2006-05-23 | 2007-11-29 | Aurobindo Pharma Limited | Process for preparing nateglinide b-type crystals |
| KR100837843B1 (ko) * | 2006-12-26 | 2008-06-13 | 씨제이제일제당 (주) | 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물 |
| WO2011157986A1 (en) | 2010-06-14 | 2011-12-22 | Cipla Limited | A process for the preparation of nateglinide |
| US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
| US9642915B2 (en) | 2012-05-07 | 2017-05-09 | Cellix Bio Private Limited | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| CA2872975A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
| US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
| JP2015521174A (ja) * | 2012-05-08 | 2015-07-27 | セリックスビオ プライヴェート リミテッド | 糖尿病の治療のための組成物および方法 |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| EP2852570B1 (en) | 2012-05-23 | 2020-04-22 | Cellixbio Private Limited | Composition for the treatment of inflammatory bowel disease |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| CA2873104A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of mucositis |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| CN104603097A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗多发性硬化症的组合物和方法 |
| US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
| US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
| CN104364231A (zh) | 2012-09-08 | 2015-02-18 | 塞利克斯比奥私人有限公司 | 用于治疗炎症和脂质异常的组合物和方法 |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| EP3004049B1 (en) | 2013-06-04 | 2018-09-05 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| WO2016051420A1 (en) | 2014-09-29 | 2016-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| CN104402756B (zh) * | 2014-11-27 | 2016-08-31 | 天方药业有限公司 | 一种高纯度那格列奈的制备方法 |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| SG11201705524SA (en) | 2015-01-06 | 2017-08-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of inflammation and pain |
| CN109369443A (zh) * | 2018-11-05 | 2019-02-22 | 扬子江药业集团江苏海慈生物药业有限公司 | 一种新的那格列奈h晶型的制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6354321A (ja) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
| AU615966B2 (en) * | 1987-12-04 | 1991-10-17 | Takeda Chemical Industries Ltd. | Crystals of cephem hydrochloride |
| US5463116A (en) * | 1991-07-30 | 1995-10-31 | Ajinomoto Co., Inc. | Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them |
| DK0526171T3 (da) | 1991-07-30 | 1997-08-25 | Ajinomoto Kk | Krystaller af N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanin og fremgangsmåder til fremstilling deraf |
| DE69740161D1 (de) * | 1996-11-15 | 2011-05-12 | Ajinomoto Kk | Nateglinide-Tablettenzubereitungen |
| US6844006B1 (en) * | 1999-07-09 | 2005-01-18 | Pennfield Oil Company | Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions |
| HK1049622A1 (en) * | 1999-12-28 | 2003-05-23 | Ajinomoto Co., Inc. | Oral preparations for diabetes |
| EP1283054A4 (en) * | 2000-03-17 | 2006-04-12 | Ajinomoto Kk | MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF |
| DE60129728T2 (de) * | 2000-10-18 | 2008-04-24 | Ajinomoto Co., Inc. | Verfahren zur herstellung von nateglinid-kristallen |
| CA2425533C (en) * | 2000-10-18 | 2010-04-20 | Ajinomoto Co., Inc. | Methods for producing acylphenylalanine |
| DK1334720T3 (da) * | 2000-10-24 | 2009-01-19 | Ajinomoto Kk | Nateglinid-indeholdende fremstillinger |
| US7411089B2 (en) | 2002-04-15 | 2008-08-12 | Ajinomoto Co., Inc. | Nateglinide crystals |
-
2001
- 2001-10-23 DK DK01976819T patent/DK1334964T3/da active
- 2001-10-23 BR BR0114846-0A patent/BR0114846A/pt not_active IP Right Cessation
- 2001-10-23 PT PT01976819T patent/PT1334964E/pt unknown
- 2001-10-23 JP JP2002537707A patent/JP4225057B2/ja not_active Expired - Fee Related
- 2001-10-23 EP EP01976819A patent/EP1334964B1/en not_active Expired - Lifetime
- 2001-10-23 AU AU2001296001A patent/AU2001296001A1/en not_active Abandoned
- 2001-10-23 MX MXPA03003575A patent/MXPA03003575A/es active IP Right Grant
- 2001-10-23 RU RU2003111948/04A patent/RU2275354C2/ru not_active IP Right Cessation
- 2001-10-23 CN CNB018212999A patent/CN100422143C/zh not_active Expired - Fee Related
- 2001-10-23 AT AT01976819T patent/ATE370115T1/de active
- 2001-10-23 WO PCT/JP2001/009293 patent/WO2002034713A1/ja not_active Ceased
- 2001-10-23 KR KR1020037005671A patent/KR100810930B1/ko not_active Expired - Fee Related
- 2001-10-23 ES ES01976819T patent/ES2288997T3/es not_active Expired - Lifetime
- 2001-10-23 CA CA002426745A patent/CA2426745C/en not_active Expired - Fee Related
- 2001-10-23 DE DE60130014T patent/DE60130014T2/de not_active Expired - Lifetime
- 2001-10-24 TW TW090126305A patent/TWI293290B/zh not_active IP Right Cessation
-
2003
- 2003-04-24 US US10/421,888 patent/US20030229249A1/en not_active Abandoned
-
2007
- 2007-06-04 US US11/757,769 patent/US7544834B2/en not_active Expired - Fee Related
- 2007-08-28 CY CY20071101136T patent/CY1106839T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2002034713A1 (ja) | 2004-03-04 |
| CY1106839T1 (el) | 2012-05-23 |
| EP1334964B1 (en) | 2007-08-15 |
| RU2275354C2 (ru) | 2006-04-27 |
| US7544834B2 (en) | 2009-06-09 |
| ATE370115T1 (de) | 2007-09-15 |
| DK1334964T3 (da) | 2007-09-24 |
| US20030229249A1 (en) | 2003-12-11 |
| EP1334964A1 (en) | 2003-08-13 |
| ES2288997T3 (es) | 2008-02-01 |
| CN100422143C (zh) | 2008-10-01 |
| TWI293290B (cg-RX-API-DMAC10.html) | 2008-02-11 |
| US20070232829A1 (en) | 2007-10-04 |
| CA2426745C (en) | 2009-09-15 |
| KR20030059212A (ko) | 2003-07-07 |
| BR0114846A (pt) | 2004-02-25 |
| JP4225057B2 (ja) | 2009-02-18 |
| CN1483018A (zh) | 2004-03-17 |
| WO2002034713A1 (en) | 2002-05-02 |
| CA2426745A1 (en) | 2003-04-23 |
| AU2001296001A1 (en) | 2002-05-06 |
| PT1334964E (pt) | 2007-09-20 |
| DE60130014D1 (de) | 2007-09-27 |
| DE60130014T2 (de) | 2008-05-08 |
| EP1334964A4 (en) | 2005-09-28 |
| KR100810930B1 (ko) | 2008-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003575A (es) | Procedimiento para elaborar la forma b del cristal de nateglinida. | |
| JP2017533883A (ja) | アルカリイセチオン酸塩およびアルカリビニルスルホン酸塩からタウリンを生産するための循環プロセス | |
| JP5654462B2 (ja) | 貧溶媒添加法による２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法 | |
| Sudha et al. | A novel method for the separation of mono and ortho polymorphs of paracetamol in gel matrix | |
| US20180305308A1 (en) | Industrial process for the preparation of (5s, 10s)-10-benzyl-16-methyl-11, 14, 18-trioxo-15, 17, 19-trioxa-2,7,8-trithia-12-azahenicosan-5-aminium(e)-3-carboxyacrylate salt | |
| JP2006169158A (ja) | 光学活性アミノ酸類の製造方法 | |
| CN110114333A (zh) | 赖氨酸乙酰水杨酸盐·甘氨酸颗粒的改进合成 | |
| US8357820B2 (en) | Process for producing N-protected amino acid | |
| DK182171B1 (en) | A method and apparatus for recycling urea and a product comprising a heavy aqueous phase comprising urea | |
| EP2739605B1 (en) | Process for the preparation of crystalline form i of agomelatine | |
| DE602005013382D1 (de) | Feste formen des magnesiumsalzes von (s)-omeprazol und verfahren zu deren herstellung | |
| JP3521150B2 (ja) | １，１，３−トリス（２−メチル−４−ヒドロキシ−５−第三ブチルフェニル）ブタンの製造方法 | |
| JP3959798B2 (ja) | １−（３−メトキシフェニル）エチルアミンの光学分割方法 | |
| US2616896A (en) | Synthesis of tryptamine | |
| Sarkar et al. | Investigation on polymorphic behavior of progesterone and stabilization by co-crystallization: A review | |
| JP2006045138A (ja) | １−アミノシクロプロパンカルボン酸の精製方法及び製造方法 | |
| JP5142613B2 (ja) | ヒダントイン環を有する化合物の製造方法 | |
| BE740757A (en) | Forming alkali nitrates by reaction of chlorides with - hno 3 in the presence of amines | |
| JP4840750B2 (ja) | 高純度４，４′−ジヒドロキシジフェニルスルホンの製造方法 | |
| JP2007015978A (ja) | アムロジピンベンゼンスルホン酸塩の製造方法 | |
| JPH0259817B2 (cg-RX-API-DMAC10.html) | ||
| JP2004123678A (ja) | 高純度ラクトンアクリレートおよびラクトンメタクリレートの製造方法 | |
| JPH0680037B2 (ja) | カルボキシメチルシステインのラセミ化法 | |
| JP2005247731A (ja) | （メタ）アクリル酸組成物及びその製造方法 | |
| JP2005068067A (ja) | ５，５−ジメチルピロリン−ｎ−オキサイドの精製方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |